Ventyx Biosciences has achieved its goal of securing Big Pharma commitment to its pipeline, with Eli Lilly swooping in to buy the inflammation biotech outright for $1.2 billion. The San Diego-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results